Source:http://linkedlifedata.com/resource/pubmed/id/12110502
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
11
|
pubmed:dateCreated |
2002-7-11
|
pubmed:abstractText |
Cellular determinants of sensitivity to the bifunctional alkylating agent 4-[N,N-bis(2-iodoethyl)amino]phenol (ZD2767D), the active drug produced by ZD2767 antibody-directed enzyme prodrug therapy (ADEPT), were studied. The prodrug 4-[N,N-bis(2-iodoethyl)amino]phenoxycarbonyl L-glutamic acid (ZD2767P)+activating enzyme carboxypeptidase G2 (CPG2) displayed growth inhibitory activity (IC(50) 0.04-2.2 microM) in colorectal tumour and non-small cell lung cancer (NSCLC) cell lines, and was more potent than a monofunctional ZD2767D analogue (colorectal cell lines-IC(50) 18-38 microM), synthesized for the first time. ZD2767P + CPG2 rapidly formed DNA-DNA interstrand cross-links (maximal at 10 min), and semi-quantitative analyses indicate that levels were similar in 3 of 4 cell lines studied (25-75 rad equivalents) at equitoxic (10 x IC(50)/LC(50)) concentrations. In matched HCT116 TP53 functional/non-functional cell lines, there was no significant difference in the sensitivity to ZD2767P+CPG2. Together, these results suggest that cellular sensitivity to ZD2767P+CPG2 is, in part, related to the levels of interstrand crosslinks, but that TP53 status does not markedly effect chemosensitivity.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Cross-Linking Reagents,
http://linkedlifedata.com/resource/pubmed/chemical/DNA, Neoplasm,
http://linkedlifedata.com/resource/pubmed/chemical/Nitrogen Mustard Compounds,
http://linkedlifedata.com/resource/pubmed/chemical/Prodrugs,
http://linkedlifedata.com/resource/pubmed/chemical/Tumor Suppressor Protein p53,
http://linkedlifedata.com/resource/pubmed/chemical/ZD 2767,
http://linkedlifedata.com/resource/pubmed/chemical/gamma-Glutamyl Hydrolase
|
pubmed:status |
MEDLINE
|
pubmed:month |
Jul
|
pubmed:issn |
0959-8049
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
38
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1543-52
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:12110502-Carcinoma, Non-Small-Cell Lung,
pubmed-meshheading:12110502-Cell Division,
pubmed-meshheading:12110502-Colorectal Neoplasms,
pubmed-meshheading:12110502-Cross-Linking Reagents,
pubmed-meshheading:12110502-DNA, Neoplasm,
pubmed-meshheading:12110502-Dose-Response Relationship, Drug,
pubmed-meshheading:12110502-Drug Screening Assays, Antitumor,
pubmed-meshheading:12110502-Humans,
pubmed-meshheading:12110502-Lung Neoplasms,
pubmed-meshheading:12110502-Nitrogen Mustard Compounds,
pubmed-meshheading:12110502-Prodrugs,
pubmed-meshheading:12110502-Tumor Cells, Cultured,
pubmed-meshheading:12110502-Tumor Suppressor Protein p53,
pubmed-meshheading:12110502-gamma-Glutamyl Hydrolase
|
pubmed:year |
2002
|
pubmed:articleTitle |
DNA interstrand cross-linking and TP53 status as determinants of tumour cell sensitivity in vitro to the antibody-directed enzyme prodrug therapy ZD2767.
|
pubmed:affiliation |
Cancer Research Unit, University of Newcastle, Framlington Place, NE2 4HH, Newcastle upon Tyne, UK.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|